Myelin oligodendrocyte glycoprotein antibody-associated disease
Conditions
Interventions
Gold Standard:Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
Index test:Live cell based assay and fixed cell based assay to detect MOG-IgG
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age =18 years old, male and female. 2.MOGAD is highly suspected. 3.Other inflammatory CNS disease control groups include: According to the diagnostic criteria and consensus of various diseases, the diagnosis of multiple sclerosis, Autoimmune encephalitis (except NMDAR encephalitis), Guillain-Barre syndrome (GBS), Chronic Inflammatory Demyelinating polyradiculopathy (CIDP), Retinal Cerebrovascular disease (SUSAC), POEMS syndrome (POEMS), and neuropathy were confirmed. The monoclonal gammopathy of unknown significance (MGUS), Sarcoidosis and so on. 4.The control group of non-inflammatory central nervous system diseases included: Migraine, CSVD, benign cranial hypertension, Glioma with definite diagnosis and no other autoimmune diseases. 5.Healthy controls include healthy people who have no autoimmune diseases through physical examination and other means. 6.Complete clinical data. 7.Informed consent of the patient or his guardian has been obtained.
Exclusion criteria
Exclusion criteria: 1.According to the Guidelines for Diagnosis and Treatment of Optic Neuromyelitis Spectrum Diseases (2021), patients with optic Neuromyelitis Spectrum diseases (NMOSD) with positive AQP4 were clearly diagnosed. 2.According to the Expert Consensus on the Diagnosis and Treatment of Autoimmune encephalitis in China (2022), the diagnosis was confirmed as NMDAR encephalitis. 3.Patients with positive anti-glial fibrillary acidic protein antibody (GFAP-IgG) in serum and/or cerebrospinal fluid. 4.Lack of clinical data. 5.Unqualified blood samples. 6.The patient's informed consent was not obtained. 7.Misdiagnosis in the research process went wrong in this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Clinical features of participanrs; | — |
Primary
| Measure | Time frame |
|---|---|
| Outcome of two CBA detection methods; | — |
Countries
China
Contacts
Public ContactChao Quan
Huashan Hospital, Fudan University
Outcome results
None listed